The interaction of chemokines and glycosaminoglycans (GAGs) on endothelial surfaces is a crucial step for establishing a chemotactic gradient which leads to the functional presentation of chemokines to their GPCRs and thus to activation of approaching leukocytes. Based on molecular modelling, biophysical investigations, cell-based and in vivo experiments we have developed a novel concept for therapeutically interfering with chemokine-GAG interactions, namely dominantnegative chemokine mutants with improved GAG binding affinity and knocked-out GPCR activity. These recombinant proteins displace their wild type chemokine counterparts from the natural proteoglycan coreceptors without being able to activate leukocytes via GPCRs. We will present in vitro and in vivo data which clearly demonstrate the validity of this approach which has been termed CellJamming because of the inhibitory interference during cell trafficking by our compounds.
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